



Walter J. Koch joins the scientific advisory board of AaviGen GmbH as expert for cardiovascular gene therapy development

Heidelberg, Germany - June 6, 2022 – AaviGen GmbH, a preclinical stage biotechnology company focused on the development of curative gene therapies for cardiovascular and cardiopulmonary diseases, today announced the appointment of Prof. Walther J. Koch as a member of the scientific advisory board. *“At AaviGen, we seek to translate excellent basic cardiovascular science into the next generation of a novel class of cardiovascular and cardiopulmonary adeno-associated viral based gene therapies. The exceptional expertise Prof. Koch contributes as a pioneer in the cardiac gene therapy field and world-wide leader in molecular and translational cardiovascular science will be decisive for AaviGen’s ability to transform molecular discoveries into clinical concepts”* says Prof. Patrick Most, CEO of AaviGen GmbH. Prof. Koch said, *“Through its versatile vector development platform, AaviGen moved into an ideal position to provide easy-to-use and highly effective gene therapies for common and rare diseases of the cardiovascular system that were previously inaccessible to this novel treatment. I look forward to contributing my experience in basic and translational cardiovascular gene therapy research to aid in navigating AaviGen towards successful completion of its innovative programs.”*

About AaviGen

AaviGen was founded in 2019 on the understanding that successful gene therapy requires optimized delivery of therapeutic targets to the diseased heart. AaviGen’s scientific approach is documented in numerous peer-reviewed scientific publications and validated by its founders’ track record in scientific innovations for the diagnosis and treatment of cardiac diseases, including gene therapy medicinal products. For more information, please see: www.aavigen.com

AaviGen Investor and Media Contact

Prof. Dr. Marc Lerchenmüller, Chief Financial Officer and Managing Director
AaviGen, Heidelberg, Germany
T: +49 6221 568900
M: +49 151 51646589
marc.lerchenmueller@aavigen.com

AaviGen’s Forward-Looking Statements

This press release contains statements that constitute “forward looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions, or projections of the company regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the company’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” or “expect,” “may,” “will,” “would,” “could,” “potential,” “intend,” or “should,” the negative of these terms or similar expressions. Forward looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking



statements are not a guarantee of the company's performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, ability to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law.